Clonazepam

# Research Output: Clonazepam

---

## Chemical Identity

**PubChem CID:** 2802 (api_verified via PubChem lookup [Ref 1])

**Molecular Formula:** C₁₅H₁₀ClN₃O₃ [Ref 1]

**Molecular Weight:** 315.71 g/mol [Ref 1]

**IUPAC Name:** 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one [Ref 1]
— Matches the seed data systematic name exactly. No discrepancy.

**InChIKey:** DGBIGWXXNGSACT-UHFFFAOYSA-N [Ref 1]

**CAS Number:** 1622-61-3 (widely cited; not directly confirmed via API in this research run — flag for editorial verification)

**SMILES:** Not returned by the PubChem API tool in this run. The canonical SMILES for CID 2802 is known from the database but should be retrieved programmatically for the article record. **FLAG: SMILES not directly verified via API call this run.** Standard SMILES per PubChem: `O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc21`

**Seed Data Notes:**
- Molecular formula, weight, and IUPAC name in the seed data were all blank; PubChem confirms all three above.
- No discrepancies with seed-level data.

**Physical Properties (gaps noted):**
- Melting point: Not recovered from primary API sources this run. Literature reports ~237–238°C. **FLAG: Unverified this run — editorial confirmation needed.**
- Solubility: Poorly water-soluble; highly lipid-soluble. Quantitative data not found in primary sources accessed. **FLAG: Confirm against DrugBank or original physicochemical characterization.**
- Stereochemistry: Clonazepam is achiral (no stereocenters). No active isomer distinction required.

---

## Pharmacology

### Mechanism of Action

Clonazepam is a 1,4-benzodiazepine that acts as a **positive allosteric modulator (PAM) of GABA-A receptors** — enhancing the frequency of chloride channel opening in response to GABA, leading to neuronal hyperpolarization and reduced excitability throughout the CNS (Sankar 2012 [Ref 3]; Navarrete et al. 2026 [Ref 4]).

Specifically, clonazepam binds to the benzodiazepine site located at the interface between α and γ subunits of the GABA-A receptor pentameric complex. The receptor subunit composition determines pharmacological character:
- **α₁ subunits**: mediate sedative, hypnotic, anticonvulsant, and amnesic effects (Sankar 2012 [Ref 3])
- **α₂ subunits**: mediate anxiolytic effects (Sankar 2012 [Ref 3])
- **α₃ and α₅ subunits**: contribute to myorelaxant and cognitive effects respectively

Unlike the 1,5-benzodiazepine clobazam, clonazepam does **not** display meaningful selectivity between α₁ and α₂ receptor complexes — it binds both with similar affinity at native rat-brain and cloned HEK293 receptor preparations (Jensen et al. 2014 [Ref 8]). This non-selectivity is consistent with its broad clinical profile spanning anticonvulsant, anxiolytic, and sedative effects.

Clonazepam also demonstrates **serotonergic activity** by enhancing serotonin synthesis, which may contribute to its panicolytic profile (StatPearls [Ref 22]).

Clonazepam displays a **relatively high molar affinity** for the benzodiazepine receptor in vitro, and the fractional extent of receptor occupancy in vivo is directly and predictably related to brain tissue concentration. Acute behavioral effects are in turn directly related to receptor occupancy (Greenblatt et al. 1987 [Ref 21]).

**Specific Ki values** at GABA-A receptor subtypes for clonazepam were not identified in primary sources accessed this run. The Jensen et al. (2014) study [Ref 8] characterizes affinity comparatively against clobazam and zolpidem but does not report absolute Ki values for clonazepam. **FLAG: Ki/EC50 data not verified from primary binding affinity study this run.**

### Pharmacokinetics

| Parameter | Value | Source |
|-----------|-------|--------|
| Oral bioavailability | ~90% | Web-retrieved (FDA label/StatPearls [Ref 22]); Greenblatt 1987 reports ≥80% [Ref 21] |
| Tmax (time to peak plasma) | 1–4 hours | StatPearls [Ref 22] |
| Elimination half-life | 20–80 hours (mean ~30–40 hours) | Greenblatt 1987 [Ref 21]; StatPearls [Ref 22] |
| Plasma protein binding | ~85% | StatPearls [Ref 22] |
| Volume of distribution | Not directly found in primary sources this run | **FLAG: Verify against primary PK literature** |
| Primary metabolic pathway | CYP3A4/CYP3A-mediated nitroreduction | StatPearls [Ref 22]; Greenblatt 1987 [Ref 21] |
| Major metabolite | 7-aminoclonazepam (pharmacologically inactive) | Greenblatt 1987 [Ref 21] |
| Secondary metabolite | Acetamido derivative (also inactive) | Greenblatt 1987 [Ref 21] |
| Primary excretion route | Renal (as glucuronide conjugates of metabolites) | Greenblatt 1987 [Ref 21] |
| Therapeutic plasma range | 0.02–0.08 mcg/mL | StatPearls [Ref 22] |

**Metabolism detail:** Biotransformation proceeds initially via reduction of the 7-nitro group (nitroreduction) to a 4-amino derivative (7-aminoclonazepam), followed by acetylation. CYP3A (including CYP3A4) plays an important role in this reduction and in subsequent oxidation. Neither the amino- nor the acetamido-metabolite possesses meaningful pharmacological activity (Greenblatt et al. 1987 [Ref 21]).

**Bioequivalence:** A randomized, single-dose crossover bioequivalence study in 36 healthy subjects (2 mg oral) confirmed comparable Cmax and AUC₀₋₉₆ᵤ between Rivotril® (Roche) and a generic formulation (Davan̤o et al. 2019 [Ref 2]). Both formulations were well-tolerated; no serious adverse events occurred.

**7-aminoclonazepam detection:**
- After a single dose: detectable in urine from ~12h post-dose, peak at 24h, detectable to 72h (Abduljabbar et al. 2024 [Ref 23]).
- After repeated chronic dosing: detectable for 9+ days (estimated 2–3 weeks) after cessation of daily use (Storhaug et al. 2012 [Ref 24]).

**Brain uptake:** In experimental studies, clonazepam diffuses passively from plasma into brain with a constant brain-to-plasma concentration ratio. The drug disappears in parallel from both brain and plasma with no evidence of sequestration in brain tissue (Greenblatt et al. 1987 [Ref 21]).

**Note on half-life vs. duration:** The elimination half-life of 30–40 hours is substantially longer than the seed data's listed total duration of 8–12 hours. This is clinically consistent — subjective/functional effects wane before full pharmacokinetic clearance — but the prolonged aftereffects period (8–48 hours) and long half-life mean residual impairment is expected long after subjective effects resolve. **FLAG: The 8–12 hour "total duration" in the seed data likely reflects subjective effect duration rather than pharmacological action duration. The generation agent should present this distinction clearly.**

---

## History

**Developer:** Leo Sternbach (1908–2005), Austro-Hungarian-born American chemist working at Hoffmann-La Roche (Nutley, NJ and Basel, Switzerland) (Britannica [Ref 35]).

**Synthesis:** Clonazepam was first synthesized in **1962** as part of Sternbach's systematic benzodiazepine drug discovery program at Hoffmann-La Roche. Sternbach had earlier discovered chlordiazepoxide (Librium, 1955) and diazepam (Valium, 1963) by the same program. Clonazepam was patented in 1960 (estimated from patent filing), with the 1962 synthesis establishing the compound's characterization (Britannica [Ref 35]).

Clonazepam was specifically designed as a **high-potency anticonvulsant** within the benzodiazepine class, exhibiting greater anticonvulsant activity compared to diazepam due to its 7-nitro substituent (which increases GABA-A receptor affinity) and the 2'-chlorophenyl group.

**First clinical use/market:** Marketed in Europe in the early 1970s as Rivotril® (Roche).

**US FDA Approval:** Approved by the FDA in **1975** under the brand name Klonopin® for seizure disorders (Lennox-Gastaut syndrome, absence seizures, complex partial seizures). Panic disorder indication added in 1997 following placebo-controlled trials (Chouinard 2004 [Ref 31]).

**Regulatory history:**
- Classified as Schedule IV under the US Controlled Substances Act since the Comprehensive Drug Abuse Prevention and Control Act (1970), effective for benzodiazepines as they came to market.
- Added to the UN Convention on Psychotropic Substances (1971) Schedule IV as benzodiazepines became internationally recognized as controlled substances.

---

## Subjective Effects

### Published Controlled Study Data

**Dowd et al. (2002) [Ref 16]** — the most direct published study of clonazepam's subjective and cognitive effects in healthy volunteers:
- 10 healthy volunteers received a **single oral dose of 3 mg clonazepam**
- **Memory and attention** were impaired throughout the entire 6-hour study period
- **Psychomotor performance** was decreased at 2 hours post-ingestion
- Subjects were **disinhibited** and critically, **did not perceive their own impairment** — a key harm-reduction relevant finding (supporting "delusions of sobriety" in the effects taxonomy)
- Temperature changes and decreased systolic blood pressure were observed

**Nardi et al. (2011) [Ref 6]** — 8-week RCT in panic disorder patients:
- Target dose 2 mg/day
- Most common adverse events (reflecting subjective effects): drowsiness/fatigue (57%), memory/concentration difficulties (24%), sexual dysfunction (11%)
- Subjects reported fewer adverse events than paroxetine-treated group

**Nardi et al. (2012) [Ref 5]** — 3-year extension (n=47, clonazepam 1.9 mg/day maintained):
- Clonazepam showed significantly better CGI-Improvement than paroxetine
- Both treatments similarly reduced panic attacks and anxiety severity
- Clonazepam had significantly fewer adverse events than paroxetine (28.9% vs 70.6%)

### Effect Domain Mapping (from controlled study + clinical trial data)

**Perception:** Dreaming enhancement (plausible from sedative effects, reduced slow-wave sleep); visual acuity suppression (consistent with CNS depression). **No direct controlled study data found specifically for these — class-level inference applies.**

**Body:** Muscle relaxation (GABA-A α2/3 mediated; clinically documented); sedation (α1 mediated; documented in all trials); dizziness (documented in all clinical trials); motor control impairment (documented, Dowd 2002 at 2h [Ref 16]); respiratory depression (documented — see Toxicity section); tactile euphoria (user-reported; not documented in controlled studies accessed). **FLAG: Tactile euphoria should be noted as lacking controlled study verification.**

**Self:** Disinhibition — directly documented in Dowd 2002 [Ref 16].

**Thinking:** Thought deceleration, analysis suppression — consistent with memory/concentration difficulties reported in Nardi 2011 [Ref 6] and cognitive impairment in Dowd 2002 [Ref 16]. Delusions of sobriety — directly documented in Dowd 2002 ("subjects were disinhibited and did not perceive their own impairment" [Ref 16]).

**Feeling:** Anxiety suppression — primary therapeutic effect, documented extensively. Emotional suppression — consistent with GABAergic dampening of limbic reactivity. Irritability — observed in some patients, particularly on discontinuation; documented as adverse effect.

### Duration Data Assessment

Seed data onset (20–60 min oral) is broadly consistent with Tmax of 1–4 hours from PK data. Peak duration (2–4 hours) and total (8–12 hours) are reasonable for subjective effects given the PK profile, though the long half-life (30–40h) means functional/cognitive effects persist beyond the subjective peak. The after-effects range of 8–48 hours reflects the pharmacokinetic reality of prolonged elimination.

---

## Safety & Toxicity

### LD50
Specific LD50 values for clonazepam were **not recovered from primary sources accessed this run**. **FLAG: LD50 not verified from primary toxicology literature.** As a class, benzodiazepines are notable for their wide therapeutic index — serious toxicity from benzodiazepine ingestion alone is rare without coingestants.

### Therapeutic Range
- Therapeutic plasma concentration: **0.02–0.08 mcg/mL**; levels >0.08 mcg/mL considered potentially toxic (StatPearls [Ref 22])

### Acute Overdose
Benzodiazepine overdose presentation is dose-dependent (StatPearls [Ref 22]):
- **Mild–moderate:** Somnolence, diplopia, slurred speech, ataxia, psychomotor impairment
- **Severe (especially with coingestants):** Respiratory depression, hypoxemia, apnea, hypotension, bradycardia, cardiac arrest, coma

The Kyong et al. (2014) [Ref 37] case series confirmed that most benzodiazepine overdoses without coingestants are **nonfatal**, with morbidity related to duration and depth of unconsciousness rather than direct toxicity. However, **polypharmacy overdoses are significantly more dangerous** — a fatal case report involved clonazepam combined with prazosin, ivabradine, and propranolol, causing severe bradycardia, hypotension, and respiratory failure requiring temporary pacemaker and lipid emulsion therapy (Patil & Patil 2025 [Ref 38]).

**Most critical toxicity risk:** Combination with CNS depressants, especially opioids and alcohol. Opioid+benzodiazepine co-use is associated with substantially elevated mortality: continuous BZD+opioid use carries adjusted hazard ratio of 1.78 for 1-year all-cause mortality vs. opioids alone (Su et al. 2026 [Ref 41]).

**Flumazenil reversal (antidote):**
- Flumazenil is a competitive benzodiazepine antagonist that can reverse BZD-induced CNS depression
- However, it is **not recommended for routine use**: meta-analysis of 13 RCTs (994 patients) showed significantly more adverse events in flumazenil vs. placebo groups (RR 2.85), including supraventricular arrhythmia and convulsions (Penninga et al. 2016 [Ref 29])
- Resedation occurs in ~30% of flumazenil-treated cases (Kyong et al. 2014 [Ref 37])
- Contraindicated in patients with BZD-dependent seizure disorders, tricyclic antidepressant overdose, or chronic BZD dependence (StatPearls [Ref 22])

### Chronic Toxicity
- **Cognitive impairment:** BZD use is an independent risk factor for cognitive decline in older adults (Teverovsky et al. 2024 [Ref 25]); chronic diazepam impairs LTP and dendritic spine density in hippocampal neurons of middle-aged mice (Furukawa et al. 2021 [Ref 34])
- **Falls and fractures:** Clonazepam is listed as a **Potentially Inappropriate Medication** per the AGS Beers Criteria due to risk of cognitive dysfunction, delirium, falls, and fractures in older adults (StatPearls [Ref 22])
- **Paradoxical reactions:** High doses can cause manic-like behavior, agitation, and rage (paradoxical disinhibition). A case report documented frank mania in a patient receiving 8 mg/day clonazepam (Dorevitch 1991 [Ref 45])

### Organ Toxicity
- **Hepatic:** Caution required; drug accumulation risk in hepatic impairment; contraindicated in severe liver disease (StatPearls [Ref 22])
- **Hematologic:** Rare thrombocytopenia documented; requires CBC monitoring in long-term use (StatPearls [Ref 22])
- **Respiratory:** Respiratory depression — particularly concerning in patients with COPD, sleep apnea, or those co-administered other CNS depressants

### Pregnancy / Lactation
- Former FDA Category D; neonatal risk includes **floppy infant syndrome** (hypotonia, poor feeding, respiratory distress) and neonatal withdrawal symptoms, particularly with late third-trimester exposure (McElhatton 1994 [Ref 19])
- Population-based case-control teratology study found association between clonazepam use in pregnancy and risk of congenital abnormalities (Eros et al. 2002 [Ref 18]); however, disentangling drug effects from underlying maternal illness is methodologically challenging
- Clonazepam is excreted into breast milk; levels are generally low but metabolism is impaired in neonates; breastfeeding ideally avoided (McElhatton 1994 [Ref 19])

### Contraindications (from literature)
- Narrow-angle glaucoma
- Severe hepatic impairment/liver disease
- Hypersensitivity to clonazepam or any benzodiazepine
- Respiratory compromise (relative contraindication — caution required)
- Concurrent opioid use without careful benefit-risk assessment (FDA black box warning class)
- Pregnancy (especially first and third trimesters)

---

## Harm Reduction

### Published Risk Reduction Strategies

**Avoid coingestants:** The single most important harm reduction point. Clonazepam combined with opioids (including prescribed methadone, heroin, fentanyl), alcohol, or other CNS depressants dramatically increases respiratory depression risk. Continuous opioid+BZD use carries 78% higher 1-year mortality than opioids alone (Su et al. 2026 [Ref 41]). Eight principles for safer prescribing include explicit caution about concomitant benzodiazepine and opioid use (Webster et al. 2015 [Ref 17]).

**Do not abruptly discontinue:** Abrupt cessation after physical dependence can precipitate life-threatening withdrawal including seizures and status epilepticus (StatPearls [Ref 22]). Gradual taper — typically using a long-acting benzodiazepine — is required.

**Driving and operating machinery:** Cognitive and psychomotor impairment persists beyond subjective intoxication (Dowd et al. 2002 [Ref 16]). Users should not drive while dosing.

**Pregnancy counseling:** Women of childbearing age should receive counseling regarding teratogenic risk, neonatal withdrawal, and floppy infant syndrome (McElhatton 1994 [Ref 19]).

**Elderly patients:** Beers Criteria explicitly identifies clonazepam as potentially inappropriate in older adults due to fall, fracture, and delirium risk (StatPearls [Ref 22]).

**Drug testing context:** 7-aminoclonazepam is the primary urinary biomarker; detectable up to 72h after a single dose and potentially 2–3 weeks after chronic use cessation (Storhaug et al. 2012 [Ref 24]; Abduljabbar et al. 2024 [Ref 23]).

**Flumazenil should not be self-administered:** Only appropriate in monitored clinical settings; risks include seizure provocation and arrhythmia (Penninga et al. 2016 [Ref 29]).

---

## Tolerance & Dependence

### Tolerance Development

Tolerance to most of clonazepam's therapeutic effects develops with continued use. The underlying neurobiological mechanism is extensively characterized:

1. **Receptor internalization and synaptic loss:** Prolonged BZD exposure causes dynamin-dependent internalization of surface GABA-A receptors via a PLC-δ/Ca²⁺/calcineurin signaling cascade, leading to gradual disassembly of inhibitory synapses (Nicholson et al. 2018 [Ref 7])

2. **α₁ subunit transcriptional downregulation:** Chronic BZD exposure reduces GABA-A α₁ subunit gene expression via an L-type voltage-gated calcium channel (L-VGCC) → Ca²⁺ → PKA → CREB/ICER signaling pathway; calcium influx appears to be the initiating event (Foitzick et al. 2020 [Ref 9]; González Gómez et al. 2023 [Ref 43])

3. **Gephyrin scaffold destabilization:** Chronic BZD treatment triggers gephyrin scaffold shrinkage, reducing the synaptic surface area available for GABA-A receptor anchoring, with γ2-GABA-A receptors accumulating extrasynaptically (Chapman et al. 2025 [Ref — unlisted, see PMID 40686502])

4. **Compensatory glutamatergic sensitization:** Downregulated GABAergic inhibition is accompanied by compensatory sensitization of NMDA and AMPA receptor systems, which underlies withdrawal excitotoxicity (Navarrete et al. 2026 [Ref 4])

**Seed data** states tolerance builds "within a couple of days" — this is consistent with published molecular data showing rapid (within days) receptor adaptation begins with sustained exposure. The full reset of 10.5 days is not directly confirmed in the primary sources accessed this run. **FLAG: The 10.5-day full tolerance reset figure is not verified against a primary source and should be reviewed.**

### Dependence

Physical dependence develops with regular use. Key clinical characterization:

- **Withdrawal syndrome** (on abrupt cessation): anxiety, irritability, insomnia, tremors, tachycardia, sweating, seizures, hallucinations, psychosis, and potentially **status epilepticus** (StatPearls [Ref 22]; Navarrete et al. 2026 [Ref 4])
- Management requires gradual dose taper, often substituting a long-acting BZD (diazepam); flumazenil slow infusion has been studied as a detoxification method, with 53% abstinent at 6 months in one series (Quaglio et al. 2012 [Ref 30])
- Psychological dependence is also significant — compulsive redosing is documented as a behavior pattern
- The seed data states "extremely physically and psychologically addictive" — this is consistent with published literature characterizing benzodiazepines as carrying significant dependence liability, though the comparative severity (vs. opioids, alcohol) should be contextualized. BZD dependence is distinct from opioid dependence but is medically serious and potentially life-threatening on withdrawal (Navarrete et al. 2026 [Ref 4])

---

## Interactions

### Critical Interactions

**Opioids (BLACK BOX WARNING):**
Concurrent use of clonazepam and opioid analgesics or illicit opioids carries risk of profound sedation, respiratory depression, coma, and death. This combination is the subject of an FDA Black Box Warning. Retrospective cohort data quantify the risk: continuous BZD+opioid use increases 1-year mortality by 78% (aHR 1.78) vs. opioids alone (Su et al. 2026 [Ref 41]). Case crossover study confirms elevated death risk with acute concomitant use (Yang et al. 2020 [Ref 42]).

**Alcohol:**
Alcohol potentiates GABA-A receptor activity via overlapping but distinct mechanisms; combined with clonazepam, results in synergistic CNS and respiratory depression. StatPearls [Ref 22] lists alcohol as a cause of severe CNS depression, respiratory compromise, and death.

**Other CNS depressants** (antidepressants, antipsychotics, antihistamines, other benzodiazepines, barbiturates, general anesthetics, muscle relaxants): Enhanced sedation; additive respiratory depression risk.

### Pharmacokinetic Interactions (CYP3A4)

**CYP3A4 Inducers (reduce clonazepam plasma levels):**
- Carbamazepine — a potent CYP3A4 inducer; accelerates clonazepam metabolism, reducing plasma concentrations to clinically relevant lower levels (Spina et al. 1996 [Ref 28])
- Phenobarbital, phenytoin — similarly reduce clonazepam levels via CYP3A4/CYP enzyme induction (StatPearls [Ref 22]; noted in felbamate interaction study [Ref 27])
- Rifampicin, St. John's Wort — class-level CYP3A4 inducers expected to reduce clonazepam exposure

**CYP3A4 Inhibitors (increase clonazepam plasma levels — toxicity risk):**
- Azole antifungals: clarithromycin, itraconazole, ketoconazole (StatPearls [Ref 22])
- HIV protease inhibitors/ritonavir combinations (including nirmatrelvir/ritonavir [Paxlovid]) — clinically significant interaction noted (StatPearls [Ref 22])

**Felbamate:** No clinically relevant pharmacokinetic interaction with clonazepam demonstrated (Glue et al. 1997 [Ref 27]).

### Other Interactions

**Kratom:** Increased CNS depression and death risk — noted in current clinical references (StatPearls [Ref 22]).

**Sodium valproate:** Combined use of clonazepam and valproate has been associated with **absence status epilepticus** in some patients — a paradoxical proconvulsant effect documented in the literature. **FLAG: This interaction should be prominently flagged in the article — safety-critical.**

---

## Legal Status

| Jurisdiction | Schedule/Class | Framework |
|---|---|---|
| **United States** | Schedule IV (controlled substance) | DEA / Controlled Substances Act 1970 [Refs 10, 36] |
| **United Kingdom** | Class C / Schedule 4 | Misuse of Drugs Act 1971 / Misuse of Drugs Regulations 2001 [Ref 36] |
| **Canada** | Schedule IV | Controlled Drugs and Substances Act (CDSA); listed under Item 18, Schedule IV [Ref 36] |
| **Australia** | Schedule 4 Appendix D (S4D) | Therapeutic Goods Administration / Standard for Uniform Scheduling of Medicines and Poisons [Ref 36] |
| **International** | Schedule IV | UN Convention on Psychotropic Substances 1971 [Ref 36] |
| **European Union** | Prescription-only medicine; national scheduling varies by member state | No uniform EU schedule; most EU countries Schedule III/IV equivalent via national law |

**Prescribing restrictions:** In the US, Schedule IV permits up to 5 refills within 6 months from date of issue (Preuss et al. 2026 [Ref 10]). In Australia, S4D status imposes additional recording and prescription requirements beyond standard S4 due to recognized addiction/abuse risk.

**No analog act applicability:** Clonazepam is a named substance under the CSA; analog act does not apply.

---

## Clinical Trials

**No major active Phase II–IV trials specifically investigating clonazepam as a primary intervention were identified** in the ClinicalTrials.gov search.

**Historical/established trials context:**
- FDA approval for LGS (epilepsy) was based on controlled clinical trials conducted in the early 1970s; eight ASMs are now FDA-approved for LGS, with clonazepam being the earliest (Samanta et al. 2025 [Ref 11])
- Panic disorder approval (1997) was based on double-blind placebo-controlled trials establishing efficacy; long-term comparative studies vs. paroxetine followed (Nardi et al. 2011–2012 [Refs 5, 6, 20])
- AASM-recommended for REM sleep behavior disorder based on accumulated observational and prospective study data (During et al. 2025 [Ref 12])

**NCT02690844** — Clonazepam for Burning Mouth Syndrome; Phase 4; **WITHDRAWN** (University of Alberta) [Ref from Clinical Trials search].

**Observation:** The lack of new major clinical trials for clonazepam reflects its established status as a decades-old generic drug. Most current research investigates it as a comparator, active control, or as part of combination pharmacotherapy studies.

---

## Community Feedback Analysis

**No community feedback was submitted** in Part A2 of the brief. No contributor corrections to investigate.

---

## Gaps & Flags

### Safety-Critical Flags

1. **⚠️ SMILES missing from database:** Seed data SMILES field is blank. PubChem CID 2802 confirmed; SMILES should be populated from PubChem canonical SMILES. Standard SMILES: `O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc21` — requires programmatic verification.

2. **⚠️ Valproate + clonazepam interaction — absence status epilepticus risk:** This is a clinically important safety signal noted in neurology literature. The interaction should be prominently flagged in the interactions section. Not confirmed from a primary source in this research run; requires editorial verification.

3. **⚠️ Tolerance reset (10.5 days) not verified:** The seed data's "full reset: 10.5 days" figure was not confirmed from any primary source accessed. This is likely derived from community consensus or structural inference. Should be reviewed by editorial team before publication.

4. **⚠️ LD50 not recovered from primary literature:** No LD50 data found via API searches. The seed data notes "low toxicity" for acute toxicity — this is consistent with published literature characterizing benzodiazepines' wide therapeutic index, but the specific LD50 value is unverified. Sources suggest the actual lethal dose of clonazepam alone is very high; most fatalities involve polydrug combinations. Generation agent should not cite a specific LD50 number without primary source verification.

5. **⚠️ "Seizure threshold reduction" listed in effects taxonomy:** Clonazepam primarily has anticonvulsant (seizure threshold-raising) effects. "Seizure threshold reduction" may refer to paradoxical effects in withdrawal or to specific populations. This apparent contradiction with the substance's primary anticonvulsant action should be clarified in the article — likely this effect manifests during withdrawal/rebound, not acute administration.

6. **⚠️ Tactile euphoria in effects taxonomy:** Not documented in controlled studies accessed. This is likely a user-reported effect. Article should label it as such.

### Data Gaps

7. **Ki/EC50 values at GABA-A receptor subtypes:** Precise binding affinity values for clonazepam were not identified in primary sources this run. Jensen et al. 2014 [Ref 8] provides comparative data but not absolute Ki values for clonazepam alone.

8. **Volume of distribution:** Not recovered from primary API sources.

9. **Physical properties (melting point, solubility):** Not confirmed from primary sources. Melting point reportedly ~237–238°C; solubility is low in water, high in organic solvents.

10. **CAS number verification:** CAS 1622-61-3 is widely cited but was not confirmed via API call this run.

11. **Bioavailability primary source:** The ~90% oral bioavailability figure comes from web-retrieved sources (FDA label, StatPearls). Greenblatt 1987 [Ref 21] states ≥80%. A primary pharmacokinetic study in humans establishing exact bioavailability was not identified in this run.

12. **Duration data primary source:** The seed data's duration values (onset 20–60 min, peak 2–4h, offset 3–6h, total 8–12h, aftereffects 8–48h) are generally consistent with PK data but no specific controlled challenge study measuring subjective duration was identified. The Dowd et al. 2002 study [Ref 16] used a 6-hour assessment window.

### Contradictions Between Seed Data and Published Sources

- **None major.** The seed data characterization is broadly consistent with published literature. Key additions: this research establishes the synthesis year (1962), FDA approval year (1975), developer identity (Leo Sternbach / Hoffmann-La Roche), confirmed CID 2802 and molecular identity, confirmed CYP3A4 metabolism, and confirmed 7-aminoclonazepam as primary metabolite.

- **"Toxicity: acute: high"** in seed data: This appears to conflict with published literature characterizing benzodiazepines as having a *low* acute toxicity when taken alone (wide therapeutic index, rare fatal monodrug overdose). The StatPearls [Ref 22] entry confirms the therapeutic range is 0.02–0.08 mcg/mL but notes that serious toxicity primarily occurs with coingestants. The seed data's "Notes: low toxicity, potentially lethal when mixed with depressants" is internally contradictory (high toxicity stated but then low toxicity noted). Generation agent should reconcile: **acute toxicity of clonazepam alone is LOW; toxicity in combination with depressants is HIGH.** **FLAG: This contradiction in the seed data should be surfaced in the generated article.**